Two medicines, side by side
Fesoterodine vs mirabegron
Fesoterodine and mirabegron are both labeled for overactive bladder. Drugs@FDA records approvals of fesoterodine since 2008 and of mirabegron since 2012. Pharmacies paid $0.794 per fesoterodine ER 4 mg tablet and $9.39 per mirabegron ER 50 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the fesoterodine FDA label on DailyMed (effective April 7, 2026); the mirabegron FDA label on DailyMed (effective December 24, 2025).
Highlights of the fesoterodine record
Fesoterodine (Toviaz) · label of April 7, 2026
Used for
From the label: indicationsToviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. […]
On the market
- Earliest approval on file
- October 31, 2008
- Generic labelers
- 11 labelers
- Pharmacy cost
- $0.794 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the mirabegron record
Mirabegron (Myrbetriq) · label of December 24, 2025
Used for
From the label: indicationsMirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. […]
On the market
- Earliest approval on file
- June 28, 2012
- Generic labelers
- 8 labelers
- Pharmacy cost
- $9.39 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Source: FDA drug labels via openFDA (Fesoterodine label of April 7, 2026, Mirabegron label of December 24, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do fesoterodine and mirabegron differ on the record?
How each works, in its label's words: Fesoterodine, “Fesoterodine is a competitive muscarinic receptor antagonist.”; Mirabegron, “Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR.”
Half-life, in each label's words: Fesoterodine, “The terminal half-life of the active metabolite is approximately 4 hours following an intravenous administration.”; Mirabegron, “Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) …”
Generics: fesoterodine since 2015; mirabegron since 2019 (Drugs@FDA).
| Fesoterodine | Mirabegron | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Pharmacologic class | n/a | beta3-Adrenergic Agonist |
| How it works (label) | Fesoterodine is a competitive muscarinic receptor antagonist. | Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. |
| Half-life (label) | The terminal half-life of the active metabolite is approximately 4 hours following an intravenous administration. | Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) of mirabegron is approximately 50 hours in patients. |
| Earliest approval on file (Drugs@FDA) | October 31, 2008 | June 28, 2012 |
| First generic approved | December 10, 2015 | December 27, 2019 |
| Generic labelers (NDC) | 11 labelers | 8 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.794 per tablet (Fesoterodine ER 4 mg tablet) | $9.39 per tablet (Mirabegron ER 50 mg tablet) |
| 12-month price change | -10% | -2% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 10,773 | 38,466 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Fesoterodine label, drug interactionsDRUG INTERACTIONS 7.1 Antimuscarinic Drugs Coadministration of Toviaz with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
Source: FDA drug labels via openFDA
What next?
- Alternatives to fesoterodine
- every medicine labeled for the same conditions